Vasculitis & polymyalgia rheumatica
Effectiveness of a two-year tapered course of tocilizumab in patients with giant cell arteritis: A single-centre prospective study
Authors' conclusion
Tocilizumab tapered over a two-year period was effective to induce and maintain remission in GCA. Relapses on tocilizumab were minor and responded to incremental changes in therapy. A significant proportion of patients relapsed in the 6 months after therapy suspension.
Study context
- Population
- Giant cell arteritis (GCA) patients eligible for tocilizumab
- Participants
- 23 patients
- Outcome
- Relapse-free survival at month 6 after tocilizumab suspension
- Follow-up
- Month 6 after tocilizumab suspension
Methodological detailssingle-centre, single-arm
- Single-centre
- Single-arm
Main finding
As reported in the abstract
Relapse in the 6 months after tocilizumab discontinuation
Tocilizumab
26%
6 of 23
Observational data: associations, not effects.
Further findings
Clinical relapse during weekly tocilizumab (first 12 months)
- Patients with clinical relapse
- 4 (17%)
Safety
- No new or unexpected safety findings identified
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Effectiveness of a two-year tapered course of tocilizumab in patients with giant cell arteritis: A single-centre prospective study. Semin Arthritis Rheum. Published 9 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →